Esperion Therapeutics to price $85 million public sale of its shares

Bookrunners JPMorgan and BofA Merrill Lynch will assist with sale

By Devika Patel

Knoxville, Tenn., Oct. 14 – Esperion Therapeutics, Inc. will price an $85 million public offering of common stock with a $12.75 million greenshoe, according to a preliminary prospectus supplement filed Tuesday with the Securities and Exchange Commission.

J.P. Morgan Securities LLC and BofA Merrill Lynch are the joint bookrunning managers.

Proceeds will be used for development, clinical studies, working capital and general corporate and administrative expenses.

The clinical-stage biopharmaceutical company is based in Plymouth, Mich.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.